Future of the Asthma Drugs Market: Strategic Analysis and Forecast to 2034

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Asthma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for asthma drugs has seen significant growth in the past few years. The market value is projected to rise from $23.96 billion in 2024 to a substantial $25.17 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.0%. Factors such as environmental issues, an upsurge in respiratory diseases, shifts in lifestyle, and enhancements in healthcare infrastructure have all contributed to the growth during the historic period.

Asthma Drugs Market Size Forecast: What's the Projected Valuation by 2029?
The market size for asthma drugs is projected to witness substantial growth in the upcoming years, becoming a $31.98 billion market by 2029, with a compound annual growth rate (CAGR) of 6.2%. Factors contributing to the growth in the predicted period are heightened air pollution levels, the rising elderly population, growing cognizance about healthcare, trends in customized medicine, and advancements in biopharmaceuticals. The forecast period also sees trends such as small molecule therapies, asthma care at home, therapies guided by biomarkers, breakthroughs in therapies for severe asthma, and partnerships for research on asthma.

View the full report here:
https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

What Are the Drivers Transforming the Asthma Drugs Market?
The rise in asthmatic conditions is anticipated to fuel the expansion of the asthma medicine industry in the future. Asthma is a chronic disease characterized by swelling and inflammation of the airways, leading to their narrowing, thereby affecting the air travel from the mouth and nose to the lungs. The increasing incidence of asthma has triggered heightened efforts for discovering novel asthma drugs to treat these conditions. For instance, as reported by Asthma + Lung UK, a UK-based charitable organization supporting people with lung diseases, the number of deaths in England due to asthma was 1,146 in 2021, which saw considerable growth in 2022 to 1,236, underscoring a worrying amplification of fatalities linked with this disease over the year's span.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11924&type=smp

What Long-Term Trends Will Define the Future of the Asthma Drugs Market?
Leading enterprises in the asthma drugs market are emphasizing the progression of innovations like fixed-dose combination (FDC) drugs with the aim of bettering the treatment effectiveness and patient consistency. A fixed-dose combination (FDC) drug is a medicinal solution that has more than one active component merged into one dosage form, such as a pill, capsule, or inhaler. For example, Glenmark Pharmaceuticals, a pharmaceutical firm from India, in June 2022, rolled out a product called Indamet, a fixed-dose combination (FDC) drug, in India for treating patients with unmonitored asthma. This revolutionary treatment unites Indacaterol, a long-lasting beta-agonist, with Mometasone Furoate, an inhaled corticosteroid, and comes in various potencies, including Indacaterol 150 mcg with Mometasone at doses of 80 mcg, 160 mcg, and 320 mcg. Indamet is formulated for a once-a-day dose and is aimed at adults and teenagers who are 12 years and above.

Which Segments in the Asthma Drugs Market Offer the Most Profit Potential?
The asthma drugs market covered in this report is segmented -

1) By Type Of Asthma: Allergic, Non-Allergic
2) By Asthma Trigger Type: Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma
3) By Therapy: Preventive, Curative
4) By Drug Class: Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs
5) By End-User: Asthma Patients, COPD Patients

Subsegments:
1) By Allergic: Inhaled Corticosteroids (ICS), Leukotriene Receptor Antagonists (LTRAs), Monoclonal Antibodies
2) By Non-Allergic: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Oral Corticosteroids

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11924&type=smp

Which Firms Dominate the Asthma Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the asthma drugs market include Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC., GlaxoSmithKline PLC., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Cipla Limited, Chiesi Farmaceutici S.p.A., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals, Mundipharma International Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Hetero Drugs Limited, Alembic Pharmaceuticals Limited, Sunovion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Ltd, Innoviva Inc., Vectura Group, Circassia Group PLC, Pulmatrix Inc., Atopix Therapeutics Limited

Which Regions Offer the Highest Growth Potential in the Asthma Drugs Market?
North America was the largest region in the asthma drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11924

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe - +44 7882 955267
Asia: +91 88972 63534
Americas - +1 310-496-7795
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.